Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marc Bierings

Showing results (41-50 of 94) with videos related to

Pageof 10
Sort By:
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|May 18, 2018
Allogeneic Stem Cell Transplantation from HLA-Mismatched Donors for Pediatric Patients with Acute Lymphoblastic Leukemia Treated According to the 2003 BFM and 2007 International BFM Studies: Impact of Disease Risk on OutcomesJean-Hugues Dalle, Adriana Balduzzi, Peter Bader, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|January 27, 2009
Association between busulfan exposure and outcome in children receiving intravenous busulfan before hematologic stem cell transplantationImke H Bartelink, Robert G M Bredius, Svetlana V Belitser, et al.
Haematologica|June 12, 2013
Pediatric Acute Lymphoblastic Leukemia: Efficacy and safety of recombinant E. coli-asparaginase in infants (less than one year of age) with acute lymphoblastic leukemiaInge van der Sluis, Anja Möricke, Gabriele Escherich, et al.
Cell Stem Cell|September 8, 2021
Antiviral treatment causes a unique mutational signature in cancers of transplantation recipientsJurrian K de Kanter, Flavia Peci, Eline Bertrums, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|July 19, 2019
Transplantation in Children and Adolescents with Acute Lymphoblastic Leukemia from a Matched Donor versus an HLA-Identical Sibling: Is the Outcome Comparable? Results from the International BFM ALL SCT 2007 StudyAdriana Balduzzi, Jean-Hugues Dalle, Jacek Wachowiak, et al.
Transplantation and Cellular Therapy|November 10, 2021
Umbilical Cord Blood Transplantation after Graft Failure from a Previous Hematopoietic Stem Cell TransplantationFernanda Volt, Annalisa Ruggeri, Graziana Maria Scigliuolo, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|December 27, 2007
Once-daily intravenous busulfan with therapeutic drug monitoring compared to conventional oral busulfan improves survival and engraftment in children undergoing allogeneic stem cell transplantationImke H Bartelink, Robbert G M Bredius, Tessa T Ververs, et al.
Bone Marrow Transplantation|August 6, 2020
The impact of donor type on the outcome of pediatric patients with very high risk acute lymphoblastic leukemia. A study of the ALL SCT 2003 BFM-SG and 2007-BFM-International SGJean-Hugues Dalle, Adriana Balduzzi, Peter Bader, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 8, 2008
PHOX2B is a novel and specific marker for minimal residual disease testing in neuroblastomaJanine Stutterheim, Annemieke Gerritsen, Lily Zappeij-Kannegieter, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 2, 2024
Continuous PEGasparaginase Dosing Reduces Hypersensitivity Reactions in Pediatric ALL: A Dutch Childhood Oncology Group ALL11 Randomized TrialInge M van der Sluis, Leiah J Brigitha, Marta Fiocco, et al.
Pageof 10

Showing results (41-50 of 94) with videos related to

Sort By:
Pageof 10
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|May 18, 2018
Allogeneic Stem Cell Transplantation from HLA-Mismatched Donors for Pediatric Patients with Acute Lymphoblastic Leukemia Treated According to the 2003 BFM and 2007 International BFM Studies: Impact of Disease Risk on OutcomesJean-Hugues Dalle, Adriana Balduzzi, Peter Bader, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|January 27, 2009
Association between busulfan exposure and outcome in children receiving intravenous busulfan before hematologic stem cell transplantationImke H Bartelink, Robert G M Bredius, Svetlana V Belitser, et al.
Haematologica|June 12, 2013
Pediatric Acute Lymphoblastic Leukemia: Efficacy and safety of recombinant E. coli-asparaginase in infants (less than one year of age) with acute lymphoblastic leukemiaInge van der Sluis, Anja Möricke, Gabriele Escherich, et al.
Cell Stem Cell|September 8, 2021
Antiviral treatment causes a unique mutational signature in cancers of transplantation recipientsJurrian K de Kanter, Flavia Peci, Eline Bertrums, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|July 19, 2019
Transplantation in Children and Adolescents with Acute Lymphoblastic Leukemia from a Matched Donor versus an HLA-Identical Sibling: Is the Outcome Comparable? Results from the International BFM ALL SCT 2007 StudyAdriana Balduzzi, Jean-Hugues Dalle, Jacek Wachowiak, et al.
Transplantation and Cellular Therapy|November 10, 2021
Umbilical Cord Blood Transplantation after Graft Failure from a Previous Hematopoietic Stem Cell TransplantationFernanda Volt, Annalisa Ruggeri, Graziana Maria Scigliuolo, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|December 27, 2007
Once-daily intravenous busulfan with therapeutic drug monitoring compared to conventional oral busulfan improves survival and engraftment in children undergoing allogeneic stem cell transplantationImke H Bartelink, Robbert G M Bredius, Tessa T Ververs, et al.
Bone Marrow Transplantation|August 6, 2020
The impact of donor type on the outcome of pediatric patients with very high risk acute lymphoblastic leukemia. A study of the ALL SCT 2003 BFM-SG and 2007-BFM-International SGJean-Hugues Dalle, Adriana Balduzzi, Peter Bader, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 8, 2008
PHOX2B is a novel and specific marker for minimal residual disease testing in neuroblastomaJanine Stutterheim, Annemieke Gerritsen, Lily Zappeij-Kannegieter, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 2, 2024
Continuous PEGasparaginase Dosing Reduces Hypersensitivity Reactions in Pediatric ALL: A Dutch Childhood Oncology Group ALL11 Randomized TrialInge M van der Sluis, Leiah J Brigitha, Marta Fiocco, et al.
Pageof 10